Merck & Co's Gefapixant Cuts Chronic Cough in Phase III

But Concerns Over Taste Side Effects

 
• By Kevin Grogan
  
Coughing
Prevalence Of Chronic Cough Estimated At 10% Of Adults Globally • Source: Shutterstock

More from Clinical Trials

More from R&D